• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Ethos Technologies Inc.

    2/2/26 7:02:49 AM ET
    $LIFE
    Specialty Insurers
    Finance
    Get the next $LIFE alert in real time by email
    8-K
    --12-31 false 0001788451 0001788451 2026-01-28 2026-01-28
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): January 28, 2026

     

     

    ETHOS TECHNOLOGIES INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-43065   81-3181024

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    90 New Montgomery Street, Suite 1500  
    San Francisco, CA   94105
    (Address of Principal Executive Offices)   (Zip Code)

    (415) 915-0665

    (Registrant’s Telephone Number, Including Area Code)

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Class A Common Stock, $0.0001 par value   LIFE   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01 Entry into a Material Definitive Agreement

    Exchange Agreements

    On January 28, 2026, in connection with its initial public offering (the “IPO”), Ethos Technologies Inc. (the “Company”) entered into exchange agreements (the “Exchange Agreements”) with Peter Colis and Lingke Wang, (each a “Co-Founder,” and together, the “Co-Founders”) who are both current executive officers and directors of the Company, and their respective affiliates, and entities affiliated with Accel and Sequoia Capital, the Company’s two largest stockholders. The Exchange Agreements provide for the exchange of shares of Class A common stock for shares of Class B common stock, effective immediately prior to the sale of the shares of the Company’s Class A common stock at the closing of the IPO. The Exchange Agreements are attached hereto as Exhibits 10.1 and 10.2 and are incorporated herein by reference.

    Equity Exchange Right Agreements

    On January 28, 2026, in connection with the IPO, the Company entered into equity exchange right agreements (each an “Equity Exchange Right Agreement”) with each of the Co-Founders. Each Equity Exchange Right Agreement requires the Company to exchange any shares of Class A common stock received upon the vesting and settlement of restricted stock units related to shares of Class A common stock or upon the exercise of stock options to purchase shares of Class A common stock for an equivalent number of shares of Class B common stock, upon the election of each Co-Founder. The equity exchange right applies to equity awards granted to the Co-Founders prior to the IPO. The Equity Exchange Rights Agreements are attached hereto as Exhibits 10.3 and 10.4 and are incorporated herein by reference.

    Item 5.03 Amendments to Articles of Incorporation or Bylaws

    Amendment and Restatement of Certificate of Incorporation

    On January 30, 2026, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the IPO. The Company’s board of directors (the “Board”) and the Company’s stockholders previously approved the Restated Certificate to be effective upon the closing of the IPO. The Restated Certificate is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

    Amendment and Restatement of Bylaws

    On January 30, 2026, the Company’s amended and restated bylaws (the “Restated Bylaws”) became effective in connection with the closing of the IPO. The Board and the Company’s stockholders previously approved the Restated Bylaws to be effective immediately prior to the closing of the IPO. The Restated Bylaws are attached hereto as Exhibit 3.2 and are incorporated herein by reference.

    Please see the description of the Restated Certificate and the Restated Bylaws in the section titled “Description of Capital Stock” in the final prospectus filed by the Company with the Securities and Exchange Commission on January 29, 2026, pursuant to Rule 424(b) under the Securities Act of 1933, as amended, relating to the Company’s Registration Statement on Form S-1, as amended (File No. 333-290534).


    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    No.
     

    Description

    3.1   Amended and Restated Certificate of Incorporation of Ethos Technologies Inc.
    3.2(1)   Amended and Restated Bylaws of Ethos Technologies Inc.
    10.1   Exchange Agreement among Ethos Technologies Inc., Peter Colis, Lingke Wang, and certain other affiliated parties, dated January 28, 2026.*
    10.2   Exchange Agreement among Ethos Technologies Inc., entities affiliated with Sequioa Capital and entities affiliated with Accel, dated January 28, 2026.*
    10.3   Equity Exchange Right Agreement between Ethos Technologies Inc. and Peter Colis, dated January 28, 2026*
    10.4   Equity Exchange Right Agreement between Ethos Technologies Inc. and Lingke Wang, dated January 28, 2026*.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     
    (1)

    Previously filed as Exhibit 3.4 to the Company’s Registration Statement on Form S-1, as amended (File No. 333-290534), filed with the Securities and Exchange Commission on January 20, 2026, and incorporated herein by reference.

    *

    Certain portions of this exhibit (indicated by asterisks) have been omitted because they are both not material and are the type that the Registrant treats as private or confidential.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Ethos Technologies Inc.
    Dated: February 2, 2026  
        By:  

    /s/ Peter Colis

          Peter Colis
          Chief Executive Officer
    Get the next $LIFE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIFE

    DatePrice TargetRatingAnalyst
    2/23/2026$33.00Buy
    Goldman
    2/23/2026$18.00Outperform
    Robert W. Baird
    2/23/2026$21.00Mkt Outperform
    Citizens
    2/23/2026$20.00Overweight
    Barclays
    2/23/2026$23.00Buy
    Deutsche Bank
    2/23/2026$13.00Overweight
    Analyst
    2/23/2026$15.00Buy
    Citigroup
    2/23/2026Outperform
    William Blair
    More analyst ratings

    $LIFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ethos Partners with Baseball Legend David Ortiz to Champion Life Insurance as a Family Financial Essential

    AUSTIN, Texas, May 21, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a new partnership with baseball icon and 3x world champion David Ortiz. In a new campaign, Ortiz will share his profoundly personal story to help raise awareness about why life insurance can be an essential part of every family's financial protection plan—and how Ethos makes getting that coverage simple, fast, and accessible. "I've lost people I love more than anything, and I've almost lost my own life," said David Ortiz. "When you go through something like that, you stop thinking about tomorrow and start thinking about th

    5/21/26 9:07:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    Ethos to Present at Upcoming Investor Conferences

    AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder and Chief Executive Officer, will present at the following investor conferences. Event Details: Bank of America Global Technology Conference on June 2, 2026 at 2:00 p.m. PT / 5:00 p.m. ETBaird 2026 Global Consumer, Technology & Services Conference on June 3, 2026 at 11:00 a.m. PT / 2:00 p.m. ETWilliam Blair 46th Annual Growth Stock Conference on June 4, 2026 at 7:20 a.m. PT / 10:20 a.m. ET A live webcast of the presentations will be available on Ethos's investor relations website at investor

    5/15/26 4:30:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Ethos Announces Early Lock-Up Release

    Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced the applicable price condition for a partial early lock-up release pursuant to the terms of the lock-up agreements entered into in connection with Ethos's initial public offering has been satisfied. As a result, 25% of the eligible securities held by eligible holders as of February 15, 2026 ("Eligible Securities") will be automatically released from the lock-up restrictions immediately prior to opening of trading on May 14, 2026 and may be sold into the public market. The lock-up restrictions will continue to apply to all remaining shares subject to lock-u

    5/13/26 4:35:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Botha Roelof bought $4,949,975 worth of shares (260,525 units at $19.00), converted options into 12,000,124 shares and returned 12,000,124 shares to the company (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/2/26 6:36:37 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Wheeler William J bought $4,949,975 worth of shares (260,525 units at $19.00), increasing direct ownership by 2,481% to 271,025 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:49:26 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Mullin Mark W. bought $99,997 worth of shares (5,263 units at $19.00), increasing direct ownership by 43% to 17,451 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:48:09 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Ethos Technologies with a new price target

    Goldman initiated coverage of Ethos Technologies with a rating of Buy and set a new price target of $33.00

    2/23/26 8:37:19 AM ET
    $LIFE
    Specialty Insurers
    Finance

    Robert W. Baird initiated coverage on Ethos Technologies with a new price target

    Robert W. Baird initiated coverage of Ethos Technologies with a rating of Outperform and set a new price target of $18.00

    2/23/26 8:37:19 AM ET
    $LIFE
    Specialty Insurers
    Finance

    Citizens initiated coverage on Ethos Technologies with a new price target

    Citizens initiated coverage of Ethos Technologies with a rating of Mkt Outperform and set a new price target of $21.00

    2/23/26 8:36:59 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Wang Lingke sold $1,024,561 worth of shares (46,349 units at $22.11), decreasing direct ownership by 14% to 695,302 units (SEC Form 4) (withholding tax)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    5/19/26 8:34:42 PM ET
    $LIFE
    Specialty Insurers
    Finance

    CEO and Secretary Colis Peter George sold $1,324,783 worth of shares (60,035 units at $22.07), decreasing direct ownership by 14% to 695,302 units (SEC Form 4) to satisfy withholding obligation

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    5/19/26 8:32:49 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Chief Financial Officer Capozzi Christopher M. was granted 80,287 shares and sold $1,783,698 worth of shares (80,586 units at $22.13), decreasing direct ownership by 0.04% to 665,228 units (SEC Form 4) (tax liability)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    5/19/26 8:31:21 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Ethos Technologies Inc.

    SCHEDULE 13G - Ethos Technologies Inc. (0001788451) (Subject)

    5/15/26 9:00:02 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form 144 filed by Ethos Technologies Inc.

    144 - Ethos Technologies Inc. (0001788451) (Subject)

    5/15/26 6:00:42 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form 144 filed by Ethos Technologies Inc.

    144 - Ethos Technologies Inc. (0001788451) (Subject)

    5/15/26 5:59:47 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Financials

    Live finance-specific insights

    View All

    Ethos to Announce First Quarter 2026 Financial Results on May 6, 2026

    AUSTIN, Texas, April 02, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it will release its financial results for the first quarter of 2026, which ended March 31, 2026, following the close of U.S. financial markets on Wednesday, May 6, 2026. The company's earnings press release will be made available on the Ethos Investor Relations website at investors.ethos.com. Ethos executives will host a conference call to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET the same day. The live webcast of the conference call can be found on the Ethos Investor Relatio

    4/2/26 4:05:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    Records full-year revenue of $387.6 million, growing 52% year-over-yearAchieves Net Income of $24.6 million and Adjusted EBITDA of $25.8 million in Q4, reflecting a 22% margin and a 23% Adjusted EBITDA marginDelivers third consecutive year of revenue growth greater than 50% AUSTIN, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. "We delivered a strong close to 2025 with 65% year-over-year revenue growth in Q4," said Peter Colis, CEO and Co-Founder of Ethos. "Our financial resul

    2/25/26 4:05:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

    Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged

    3/14/24 4:00:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors

    AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the appointment of William J. Wheeler to its Board of Directors. Mr. Wheeler, a seasoned executive with deep expertise across insurance, retirement services, and investment banking, joins Ethos' distinguished board, further strengthening Ethos' governance and strategic guidance as the company continues its rapid growth and innovation. Mr. Wheeler brings more than three decades of leadership experience in the financial services industry. He most recently served as Vice Chairman of Athene Holding Ltd. (NYSE:ATH), a leadin

    7/30/25 11:00:00 AM ET
    $EVR
    $LIFE
    $ATH
    Investment Managers
    Finance
    Specialty Insurers
    Life Insurance

    aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

    SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023. "We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Dr. Frederick's clinical background combined with

    1/18/24 8:00:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/14/24 1:43:55 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/13/24 4:30:17 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/9/24 8:35:54 AM ET
    $LIFE
    Specialty Insurers
    Finance